Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. (Q51501718)

From Wikidata

Jump to navigation Jump to search

scientific article published in January 1998

Language	Label	Description	Also known as
English	Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas.	scientific article published in January 1998

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

author name string

S R Patel

1

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

M A Burgess

2

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

N E Papadopolous

3

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

G Sidhu

4

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

R Gray

5

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

C Plager

6

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

J Jenkins

7

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

R S Benjamin

8

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

publication date

1 January 1998

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

16

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

1

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

87-92

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9740549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9740549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/9740549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,2-dihydro-3-[(N-methylanilino)methyl]-pyrido[3,4-b]pyrazin-7-ylcarbamate (NSC 181928).

1 reference

https://pubmed.ncbi.nlm.nih.gov/9740549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological effects and structure-activity relationships of 1,2-dihydropyrido[3,4-b]pyrazines

1 reference

https://pubmed.ncbi.nlm.nih.gov/9740549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New anticancer agents: chiral isomers of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazine-7-car bamate .

1 reference

https://pubmed.ncbi.nlm.nih.gov/9740549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9740549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose response evaluation of adriamycin in human neoplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/9740549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 1997.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9740549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence

1 reference

https://pubmed.ncbi.nlm.nih.gov/9740549

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1006078930550

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 April 2018

http://europepmc.org/abstract/MED/9740549

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51501718&oldid=2210870962"